Table 3.
Summary of patients with SARS-CoV-2-positive faecal or rectal swabs
| Author | Region | Number of patients with positive stool/rectal swab sample | Duration of positive infection (days) | Patients with positive stool/rectal sample after negative respiratory system samples | Duration after positive respiratory system samples (days) |
|---|---|---|---|---|---|
| Adult patients | |||||
| Lin et al.72 | Guangzhou, China | 46/217 (21.2%) | 3–18 | 30/46 (65.2%) | 3–15 |
| Ling et al.73 | Shanghai, China | 54/66 (81.8%) | 9–16a | 43/55 (78.2%) | 1–4 |
| Cheung et al.15 | Hong Kong, China | 9/59 (15.3%) | Data collection on presentation | NA | NA |
| Kujawski et al.74 | USA | 7/12 (58.3%) | 1–12 | 1/7 (14.3%) | 1 |
| Lo et al.75 | Macau, China | 9/9 (100%) | 1–18 | 1/9 (11.1%) | 6 |
| Young et al.76 | Singapore | 4/8 (50%) | 1–7 | 1/4 (25%) | 5 |
| Paediatric patients | |||||
| Hua et al.77 | Zhejiang, China | 32/35 (91.4%) | NA | 18/35 (51.4%) on discharge | >70 days in one child since illness onset |
| Han et al.78 | Seoul, Korea | 11/12 (91.6%) | 80% positive >3 weeks | NA | NA |
| Xu et al.79 | Guangzhou, China | 8/10 (80%) | 3–28a | 8/8 (100%) | 3–30a |
| Liu et al.80 | Shanghai, China | 8/9 (89%) | 28–66 | 8/8 (100%) | 14–52 |
| Cai et al.81 | China | 5/6 (83.3%) | 18–30a | 5/5 (100%) | 11–18 |
| Xing et al.82 | Qingdao, China | 3/3 (100%) | 6–30 | 3/3 (100%) | 8–20 |
| No distinction made | |||||
| Wu et al.83 | Zhuhai, China | 41/74 (55.4%) | 1–39 | 32/41 (78%) | 1–33 |
| Xiao et al.59 | Guangzhou, China | 39/73 (53.4%) | 1–12a | 17/39 (43.6%) | NA |
| Chen et al.84 | Wuhan, China | 28/42 (66.7%) | 1–21a | 18/28 (64.3%) | 6–10 |
| Kim et al.85 | Korea | 8/15 (53.3%) | 1–7 | 2/8 (25%) | 3–9 |
This is a table with selected studies; studies that were published before 1 Aug 2020, sample size ≥3, and proportion and duration of positive virus in the stool of the patients with COVID-19 were selected. NA, not available; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. aSome patients remain positive at last follow-up.